Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.
HIV-1 has resulted in a devastating AIDS pandemic. An effective HIV/AIDS vaccine that can be used to either, prevent HIV infection, control infection or prevent progression of the disease to AIDS is needed. In this review we discuss the use of Mycobacterium bovis BCG, the tuberculosis vaccine, as a vaccine vector for an HIV vaccine. Numerous features make BCG an attractive vehicle to deliver HIV antigens. It has a good safety profile, elicits long-lasting cellular immune responses and in addition manufacturing costs are affordable, a necessary consideration for developing countries. In this review we discuss the numerous factors that influence generation of a genetically stable recombinant BCG vaccine for HIV.
Chapman
Rosamund
R
Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory, 7925, Cape Town, South Africa. Ros.Chapman@uct.ac.za
Chege
Gerald
G
Shephard
Enid
E
Stutz
Helen
H
Williamson
Anna-Lise
AL
D016915:AIDS Vaccines / Q000009:adverse effects / Q000235:genetics* / Q000276:immunology*; D001500:BCG Vaccine / Q000009:adverse effects / Q000235:genetics* / Q000276:immunology*; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control / Q000628:therapy; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology*; D006801:Humans
D016915:AIDS Vaccines; D001500:BCG Vaccine